iSHP1-DCEXs

iSHP1-DCEXs are next-generation dendritic cell-derived exosomes (DCEXs) engineered by the genetic knockout of the non-receptor protein tyrosine phosphatase SHP1 (PTPN6) in the source dendritic cells. SHP1 acts as an intrinsic inhibitory checkpoint in dendritic cells; its removal prevents DC exhaustion and enhances the immunogenicity of the resulting exosomes. These engineered exosomes exhibit significantly increased expression of MHC-I/peptide complexes (pMHC-I) and costimulatory molecules, leading to potent stimulation of antigen-specific CD8+ T cell proliferation and tumor infiltration. Developed primarily for the treatment of aggressive cancers and brain metastases, iSHP1-DCEXs have shown efficacy in preclinical models of breast cancer brain metastases and melanoma, both as a monotherapy and in combination with PD-1 checkpoint inhibitors.

Other names

SHP1-deficient dendritic cell-derived exosomesSHP-1-deficient dendritic cell-derived exosomesSHP 1-deficient dendritic cell-derived exosomesSHP1-knockout DC-derived exosomesSHP-1-knockout DC-derived exosomesSHP 1-knockout DC-derived exosomes